Yaman, E. Et Al. 2010. Serum M30 levels are associated with survival in advanced gastric carcinoma patients. INTERNATIONAL IMMUNOPHARMACOLOGY , vol.10, no.7 , 719-722.

Yaman, E., Coskun, U., Sancak, B., Buyukberber, S., Ozturk, B., & Benekli, M., (2010). Serum M30 levels are associated with survival in advanced gastric carcinoma patients. INTERNATIONAL IMMUNOPHARMACOLOGY , vol.10, no.7, 719-722.

Yaman, Emel Et Al. "Serum M30 levels are associated with survival in advanced gastric carcinoma patients," INTERNATIONAL IMMUNOPHARMACOLOGY , vol.10, no.7, 719-722, 2010

Yaman, Emel Et Al. "Serum M30 levels are associated with survival in advanced gastric carcinoma patients." INTERNATIONAL IMMUNOPHARMACOLOGY , vol.10, no.7, pp.719-722, 2010

Yaman, E. Et Al. (2010) . "Serum M30 levels are associated with survival in advanced gastric carcinoma patients." INTERNATIONAL IMMUNOPHARMACOLOGY , vol.10, no.7, pp.719-722.

@article{article, author={Emel Yaman Et Al. }, title={Serum M30 levels are associated with survival in advanced gastric carcinoma patients}, journal={INTERNATIONAL IMMUNOPHARMACOLOGY}, year=2010, pages={719-722} }